Canada· CA-DIN-02455404
INVOKAMET
A metformin and canagliflozin product containing metformin hydrochloride + canagliflozin, registered in Canada by JANSSEN INC. The same ATC class is registered in 11 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Metformin and canagliflozin is registered in 11 of 19 countries.
Countries holding a registration under ATC A10BD16 (metformin and canagliflozin), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Metformin and canagliflozin · ATC A10BD16
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- METFORMIN HYDROCHLORIDE + CANAGLIFLOZIN
- Manufacturer
- JANSSEN INC
- Country
- Canada (CA)
- ATC code
- A10BD16
- ATC class
- Metformin and canagliflozin
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for metformin and canagliflozin.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metformin and canagliflozin · interactions on record
2 records
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Metformin and canagliflozin in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesINVOKAMETJanssen Pharmaceuticals, Inc.
- CzechiaVOKANAMETJanssen-Cilag International N.V., Beerse
- SwitzerlandVokanamet 150 mg / 1000 mg, FilmtablettenJanssen-Cilag AG
- IcelandVokanametJanssen-Cilag International NV*
- NetherlandsVokanamet 150 mg/1.000 mg filmomhulde tablettenJanssen-Cilag International NV
- SwedenVokanamet 150 mg/1000 mg Filmdragerad tablettJanssen-Cilag International NV
- PolandVokanametJanssen-Cilag International N.V.
- SpainVOKANAMET 150 MG/1000 MG COMPRIMIDOS RECUBIERTOS CON PELICULAJanssen-Cilag International N.V
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vokanamet
- Liechtenstein · Vokanamet
- Norway · Vokanamet
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fbb74bc6-dc11-488e-8f2f-3d5e6e0e516c GET /v1/drugs/fbb74bc6-dc11-488e-8f2f-3d5e6e0e516c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02455404",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "A10BD16",
"schedule": [
"Prescription"
],
"drug_code": "94221",
"strengths": [
"500 MG",
"50 MG"
],
"ahfs_class": null,
"substances": [
"METFORMIN HYDROCHLORIDE",
"CANAGLIFLOZIN"
],
"product_categorization": null
}See everything about metformin and canagliflozin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.